Concord Biotech Limited (CONCORDBIO)
Healthcare | Biotechnology
₹2120.55
-1.85% (₹39.9)
Market Overview
| Market Cap | 221843456000 |
| Volume | 55839 |
| 52W High | ₹2664.0 |
| 52W Low | ₹1327.05 |
Key Ratios
| P/E Ratio | 67.684326 |
| EPS | 31.33 |
| Beta | 0 |
| Dividend Yield | 0.0041% |
Financial Performance
Revenue Growth
0.182%
Profit Margin
0.30201998%
ROE
0.22272%
ROA
0.1558%
Stock Analysis Score: 60/100
Growth Score: 60/100
Key Strengths:
- Excellent profit margins above 15%
- Strong ROE above 15%
- Low volatility with beta below 1
- Strong operating margins above 15%
Recommendation
Buy - The stock shows good fundamentals with some room for improvement
Detailed Analysis
Growth: 0.2% revenue growth indicates weak business expansion.
Profitability: 30.2% profit margin shows excellent operational efficiency.
Returns: ROE of 22.3% demonstrates strong return on shareholder investment.
Valuation: PE ratio of 67.7x is expensive compared to market averages.
Trading Decision Guide
- Score 80-100: Consider for long-term investment with high conviction
- Score 60-79: Suitable for medium-term investment with regular monitoring
- Score 40-59: Short-term trading opportunities, maintain strict stop-losses
- Score Below 40: High-risk trading only, thorough research essential
Risk Factors
- Market Cap: ₹22184.3Cr
- Beta: 0.00 (Market Volatility)
- 52-Week Range: ₹1327.0 - ₹2664.0
Last Updated: 2025-01-23 06:54:06